• uPAR–uPA Inhibition in Breast Cancer Metastasis

  2026-10-04

  Mani et al. evaluated compound 4 as a small-molecule inhibitor of the uPAR–uPA protein–protein interaction, linking direct biochemical binding with cellular invasion assays, pharmacokinetics, and a murine breast cancer metastasis model. The results support compound 4 as a promising research template, while the preclinical design does not establish clinical efficacy or fully resolve in vivo target engagement.

• CREATE: RNA-Based Gene Editing Without DNA Templates

  2026-10-03

  The CREATE platform combines CRISPR/Cas9 targeting with the RNA-mediated reverse transcription and integration properties of human LINE-1. In the reference study, it enabled insertion of a 1.1 kb expression cassette into selected genomic loci in human cell lines and primary T cells without a DNA donor template or reported double-strand-break-dependent design.

• Fingolimod (FTY720) for Precision Immune Assays

  2026-10-02

  Fingolimod (FTY720) is more than an approved multiple sclerosis therapy: it is a powerful experimental probe of S1P-dependent lymphocyte trafficking, CNS signaling, and immune-cell localization. This guide develops an assay-centered framework linking FTY720 biology with emerging in vivo CAR-T-mimicking platforms.

• Pentoxifylline: Reliable Cell Assay Workflows

  2026-10-01

  This scenario-driven guide explains how Pentoxifylline, SKU C3816, can support reproducible viability, proliferation, nitric oxide, and cytokine experiments. It connects phosphodiesterase inhibition with practical dose selection, vehicle controls, interpretation, and supplier evaluation.

• WDR36, Glycolysis, and Human Trophectoderm Fate

  2026-10-01

  The reference study identifies WDR36 as a regulator of human blastoid formation and trophectoderm differentiation, linking this developmental function to glycolytic metabolism and interaction with LDHA. Its combined use of mouse embryos, human pluripotent stem cell-derived blastoids, transcriptomics, and targeted metabolomics provides a mechanistic framework for studying early lineage commitment, while also highlighting the limits of translating blastoid findings to human embryos.

• β-Elemene Assay Workflows for AMPK Research

  2026-09-30

  Use β-Elemene as a practical probe for adipocyte differentiation, insulin-resistance phenotypes, and AMPK-linked metabolic signaling. The same compound also supports carefully bounded extensions into neuroprotection, inflammation, cancer biology, and analytical standardization.

• HHV-7 DNA in Ocular Toxoplasmosis

  2026-09-30

  This case report describes the first, to the authors’ knowledge, detection of human herpesvirus 7 DNA in vitreous humor from an eye with recurrent ocular toxoplasmosis. Co-detection of Toxoplasma gondii and HHV-7 during refractory uveitis, followed by clinical resolution and loss of detectable DNA after treatment, supports a hypothesis of HHV-7 reactivation but does not establish causality.

• Nifedipine: A Calcium Lens on Liver Translation

  2026-09-29

  Nifedipine (BAY-a-1040) offers translational researchers a controlled way to test how L-type calcium influx shapes liver metabolism, iron handling, and disease-relevant phenotypes. By pairing calcium perturbation with PXR, CYP, viability, and transporter readouts, researchers can move beyond descriptive product testing toward mechanistically resolved models.

• Chloroquine BA1002: Practical Assay Guide

  2026-09-29

  Chloroquine BA1002 provides a defined 4-aminoquinoline perturbagen for lysosomal pH, autophagy, inflammatory signaling, malaria, and cell-response assays. This guide explains solvent handling, concentration selection, controls, and interpretation limits; it should not be used as a substitute for clinical dosing guidance or as proof of pathway-specific activity.

• DDI2–NFE2L1 Protects Cells from Ferroptosis

  2026-09-28

  The reference study identifies DDI2-mediated activation of NFE2L1 as an adaptive proteostasis response to ferroptosis. By combining ubiquitylation profiling, genetic perturbation, proteasome measurements, and pharmacological testing, it shows that disabling this pathway increases proteasome failure and ferroptotic cell death.

• ISRIB and the Biology of Accelerated Forgetting

  2026-09-28

  ISRIB (trans-isomer) offers translational researchers a way to probe how integrated stress response signaling shapes memory retention—not just memory formation. A recent mouse study links inflammation-associated accelerated forgetting to hippocampal ISR activation, while highlighting why target engagement, treatment timing, and behavioral controls matter.

• Cell Death Mechanisms in Liver Disease

  2026-09-27

  Luedde, Kaplowitz, and Schwabe synthesize evidence that hepatocyte death is not merely a marker of liver injury: its mode and context shape inflammation, fibrosis, cirrhosis, and liver cancer. Their review connects clinical biomarkers with cell-death mechanisms and highlights why therapeutic strategies must account for the responding cell type and disease stage.

• Methotrexate Workflows for DHFR and T-Cell Studies

  2026-09-26

  Use Methotrexate to probe DHFR-dependent proliferation, activated T-cell responses, and anti-inflammatory mechanisms—with a concentration-and-time workflow designed to separate growth inhibition from apoptosis. A recent membrane-chromatography comparison also offers practical guidance for choosing permeability assays, while making clear that its findings do not establish Methotrexate-specific pulmonary transport.

• Dexamethasone (DHAP): From Mechanism to Model

  2026-09-25

  Dexamethasone is more than an anti-inflammatory benchmark: its effects vary across immune, neural, stem-cell, and tumor models. This guide connects mechanism to model choice, assay design, and translational interpretation.

• BIIE 0246: Selective Neuropeptide Y Y2 Antagonist

  2026-09-25

  BIIE 0246 is a potent, selective neuropeptide Y Y2 receptor antagonist used to investigate Y2R signaling in neural, gastrointestinal, and feeding-behavior models. Its reported pharmacology supports experimental NPY Y2 receptor inhibition, but it does not establish Y2R as a mechanism in the cited epicardial-adipose arrhythmia study, which identifies NPY signaling through Y1R.

8371 records 1/559 page Next 12345 下5页 Last page